ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed 09 December 8:00AM
Realtime Data

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
42.20
Bid
41.80
Offer
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
rx7171 rx7171 3 minutes ago
Waiting for a headline in the New York Times.

“BREAKTHROUGH IN ALZHEIMERS TREATMENT”
AVXL
mick mick 3 minutes ago
right is China’s currency, the Yuan. On the left is the dollar.


China has one goal: replace the U.S. dollar as the world’s reserve currency.


And they’re getting closer to that goal each day.



In February, they got Iraq to
chipboarder chipboarder 3 minutes ago
I’m willing to believe the 12-18 months but the EvieRing isn’t it…..it’s a step in the right direction but not big enough to fuel a “big breakout”.
LQMT
Monksdream Monksdream 4 minutes ago
TOL, 10Q due DEC 9, per Seeking Alpha
https://investorshub.advfn.com/uimage/uploads/2024/12/8/sip[dIMG_3786.gif
TOL
north40000 north40000 4 minutes ago
Requirement 3---balance of equity and hardships--- should weigh heavily in Amarin's favor. The combined Hikma and Dr. Reddy deliberate deception and misleading conduct/behavior, found in their post-trial brief in the Nevada District Court, is apparent on its face, particularly in light of the detail
AMRN
betman betman 4 minutes ago
I've never seen a company advertise for a director before. I think they are just looking for funds.
FUNR
kbaz kbaz 5 minutes ago
The Beta Testing Group is Getting Bigger and Bigger......
Yes this Player (ranked 20K in Score) brand new in last 30 days..... I think the Management team is gone for the Holidays, so maybe a Next year Announcement in order. This is time for some Big Time Chat Discussions on b
FRZT
exwannabe exwannabe 6 minutes ago
Was SurvVaxM not a target of the collusive cabal with organized short attacks and ongoing price suppression like NWBO is? I'll have to check their board and see if there are any familiar FUDsters there.
You do realize that SurVaxM is Roswell Park's lead Immuno-oncology program and now in the
NWBO
mick mick 6 minutes ago
The simple fact that the commercial real estate market is causing a $6 trillion meltdown for banks and pension funds is a topic most people don’t grasp.


But there’s a way for smart investors to personally benefit from it.
Dickmo Dickmo 7 minutes ago
Looking forward to a successful fundraising and launch of this company. I like the current stock structure. Lots of room to be creative.
RMXI
nowwhat2 nowwhat2 7 minutes ago
Why would you trust someone who looks like Mark Twain
https://investorshub.advfn.com/uimage/uploads/2024/12/8/pigpxXRP_121212_8_1M_930am_OHTL_BO.jpg



https://investorshub.advfn.com/uimage/uploads/2024/12/8/djmjgXRP_121212_8_15D_930am_OHTL_BO.jpg

XRPUSD
mc73 mc73 7 minutes ago
$100 in the next 2 years, might take 3
SOUN
mick mick 7 minutes ago
most people don’t know is that pension funds are one of the biggest investors in commercial real estate.



And they’re starting to get hammered.


Pension funds like Calstrs, the California State Teachers’ Retirement System, are already taking big h
stocksrising stocksrising 8 minutes ago
And follow up data for Sickle Cell as well:

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
December 08 2024 - 12:30PM
BLUE
Elroy Jetson Elroy Jetson 8 minutes ago
Prince William who is 6'3" stands next to Donald Trump who claims he too is 6'3" in his elevator shoes.

The Donald does appear a couple of inches taller than Emmanuel Macron who is 5'7".

When Donald was arrested in New York for falsifying business records in April 2023,
mick mick 8 minutes ago
people keep working from home, it’s turning into a nightmare for downtown office districts around the country.


According to St. Louis Federal Reserve, commercial real estate prices have recently begun to nosedive.
elks elks 8 minutes ago
OTC Time is here been buying up big basket stocks good luck GRLT !!!!!
GRLT
surfer44 surfer44 8 minutes ago
Pete Townshend's Deep End - Rough Boys (Face The Face)

https://youtu.be/AfKKIQL4bHM
mick mick 9 minutes ago
money was sent to people because they were told to stay home.



That’s why we’ve had the terrible inflation we’ve had in this country the past few years.



But the lockdowns caused another problem: people stopped coming to the office.
Sirpeter Sirpeter 9 minutes ago
Yup think we may get a sling shot taking profits tomorr Then up up and away...will see...GL
AVGO
mick mick 9 minutes ago
it is estimated that 6.86 million people died worldwide.



And 1.2 million of those who died were Americans, which makes it twice as deadly as the Spanish Flu was in this country in 1918.



Some of the people we lost were my friends.
Dickmo Dickmo 10 minutes ago
Looking forward to learninghow RMXI plans to market their product. This is always the toughest and most important challenge for smaller tech companies transitioning from R&D to revenue generating mode.
RMXI
janga janga 10 minutes ago
Not for nothing the guy accomplished in six months what didn’t get accomplished in three years; give it a break: give the guy about two months more I think everyone here is going to be shocked: kicking the can?
NBRI
mick mick 10 minutes ago
Prices are now starting to go back to where they were before the start of the pandemic.

homeowners, we should be very concerned about this.



The only reason housing prices haven’t gone down faster is that the government is still borrowing $1 trillion eve

Your Recent History

Delayed Upgrade Clock